Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
Identifieur interne : 005694 ( Main/Merge ); précédent : 005693; suivant : 005695Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
Auteurs : Matthew B. Stern [États-Unis] ; Kenneth L. Marek [États-Unis] ; Joseph Friedman [États-Unis] ; Robert A. Hauser [États-Unis] ; Peter A. Lewitt [États-Unis] ; Daniel Tarsy [États-Unis] ; C. Warren Olanow [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-08.
English descriptors
- KwdEn :
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Incidence, Indans (pharmacokinetics), Indans (therapeutic use), Male, Middle Aged, Monoamine Oxidase Inhibitors (pharmacokinetics), Monoamine Oxidase Inhibitors (therapeutic use), Multicenter Studies as Topic, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson's disease, Severity of Illness Index, Time Factors, Treatment Outcome, monoamine oxidase inhibitors, monotherapy, rasagiline, safety, tolerability.
- MESH :
- chemical , pharmacokinetics : Indans, Monoamine Oxidase Inhibitors.
- chemical , therapeutic use : Indans, Monoamine Oxidase Inhibitors.
- complications : Parkinson Disease.
- drug therapy : Parkinson Disease.
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Multicenter Studies as Topic, Severity of Illness Index, Time Factors, Treatment Outcome.
Abstract
Rasagiline (N‐propargyl‐1(R)‐aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase‐B inhibitor. This study was designed to evaluate the safety, tolerability, and preliminary efficacy of rasagiline monotherapy in early Parkinson's disease (PD) patients not receiving levodopa. The study was performed as a multicenter, parallel‐group, double‐blind, randomized, placebo‐controlled, 10‐week study. Fifty‐six PD patients were randomly assigned to rasagiline mesylate 1, 2, or 4 mg once daily, or placebo. A 3‐week dose‐escalation period was followed by a 7‐week maintenance phase. At week 10, the mean (±SE) changes from baseline in total Unified Parkinson's Disease Rating Scale (UPDRS) score were −1.8 (±1.3), −3.6 (±1.7), −3.6 (±1.2), and −0.5 (±0.8) in the rasagiline 1, 2, and 4 mg/day and placebo groups, respectively. Analysis of responders showed that 28% of patients (12 of 43) receiving rasagiline had an improvement in total UPDRS score of greater than 30%, compared with none of the patients receiving placebo (P < 0.05, Fisher's exact test). The frequency and types of adverse events reported by rasagiline‐treated and placebo‐treated patients were similar. These results suggest that rasagiline monotherapy is well tolerated and efficacious in early PD. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20145
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000E54
- to stream Istex, to step Curation: 000E54
- to stream Istex, to step Checkpoint: 002717
- to stream PubMed, to step Corpus: 003388
- to stream PubMed, to step Curation: 003388
- to stream PubMed, to step Checkpoint: 003482
- to stream Ncbi, to step Merge: 000E96
- to stream Ncbi, to step Curation: 000E96
- to stream Ncbi, to step Checkpoint: 000E96
Links to Exploration step
ISTEX:06152E8AE57392DB334A8634EF1C90F690645F8ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients</title>
<author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name>
</author>
<author><name sortKey="Marek, Kenneth L" sort="Marek, Kenneth L" uniqKey="Marek K" first="Kenneth L." last="Marek">Kenneth L. Marek</name>
</author>
<author><name sortKey="Friedman, Joseph" sort="Friedman, Joseph" uniqKey="Friedman J" first="Joseph" last="Friedman">Joseph Friedman</name>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name>
</author>
<author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:06152E8AE57392DB334A8634EF1C90F690645F8A</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1002/mds.20145</idno>
<idno type="url">https://api.istex.fr/document/06152E8AE57392DB334A8634EF1C90F690645F8A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000E54</idno>
<idno type="wicri:Area/Istex/Curation">000E54</idno>
<idno type="wicri:Area/Istex/Checkpoint">002717</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Stern M:double:blind:randomized</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15300656</idno>
<idno type="wicri:Area/PubMed/Corpus">003388</idno>
<idno type="wicri:Area/PubMed/Curation">003388</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003482</idno>
<idno type="wicri:Area/Ncbi/Merge">000E96</idno>
<idno type="wicri:Area/Ncbi/Curation">000E96</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000E96</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Stern M:double:blind:randomized</idno>
<idno type="wicri:Area/Main/Merge">005694</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients</title>
<author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pennsylvania, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marek, Kenneth L" sort="Marek, Kenneth L" uniqKey="Marek K" first="Kenneth L." last="Marek">Kenneth L. Marek</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Yale University School of Medicine, New Haven, Connecticut</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Friedman, Joseph" sort="Friedman, Joseph" uniqKey="Friedman J" first="Joseph" last="Friedman">Joseph Friedman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Brown University School of Medicine, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Neurology, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, Detroit, and Clinical Neuroscience Center, Southfield, Michigan</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Beth Israel Deaconess Medical Center, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mount Sinai School of Medicine, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2004-08">2004-08</date>
<biblScope unit="vol">19</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="916">916</biblScope>
<biblScope unit="page" to="923">923</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">06152E8AE57392DB334A8634EF1C90F690645F8A</idno>
<idno type="DOI">10.1002/mds.20145</idno>
<idno type="ArticleID">MDS20145</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Incidence</term>
<term>Indans (pharmacokinetics)</term>
<term>Indans (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Monoamine Oxidase Inhibitors (pharmacokinetics)</term>
<term>Monoamine Oxidase Inhibitors (therapeutic use)</term>
<term>Multicenter Studies as Topic</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson's disease</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
<term>monoamine oxidase inhibitors</term>
<term>monotherapy</term>
<term>rasagiline</term>
<term>safety</term>
<term>tolerability</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Indans</term>
<term>Monoamine Oxidase Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Indans</term>
<term>Monoamine Oxidase Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Multicenter Studies as Topic</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Rasagiline (N‐propargyl‐1(R)‐aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase‐B inhibitor. This study was designed to evaluate the safety, tolerability, and preliminary efficacy of rasagiline monotherapy in early Parkinson's disease (PD) patients not receiving levodopa. The study was performed as a multicenter, parallel‐group, double‐blind, randomized, placebo‐controlled, 10‐week study. Fifty‐six PD patients were randomly assigned to rasagiline mesylate 1, 2, or 4 mg once daily, or placebo. A 3‐week dose‐escalation period was followed by a 7‐week maintenance phase. At week 10, the mean (±SE) changes from baseline in total Unified Parkinson's Disease Rating Scale (UPDRS) score were −1.8 (±1.3), −3.6 (±1.7), −3.6 (±1.2), and −0.5 (±0.8) in the rasagiline 1, 2, and 4 mg/day and placebo groups, respectively. Analysis of responders showed that 28% of patients (12 of 43) receiving rasagiline had an improvement in total UPDRS score of greater than 30%, compared with none of the patients receiving placebo (P < 0.05, Fisher's exact test). The frequency and types of adverse events reported by rasagiline‐treated and placebo‐treated patients were similar. These results suggest that rasagiline monotherapy is well tolerated and efficacious in early PD. © 2004 Movement Disorder Society</div>
</front>
</TEI>
<double doi="10.1002/mds.20145"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients</title>
<author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name>
</author>
<author><name sortKey="Marek, Kenneth L" sort="Marek, Kenneth L" uniqKey="Marek K" first="Kenneth L." last="Marek">Kenneth L. Marek</name>
</author>
<author><name sortKey="Friedman, Joseph" sort="Friedman, Joseph" uniqKey="Friedman J" first="Joseph" last="Friedman">Joseph Friedman</name>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name>
</author>
<author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:06152E8AE57392DB334A8634EF1C90F690645F8A</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1002/mds.20145</idno>
<idno type="url">https://api.istex.fr/document/06152E8AE57392DB334A8634EF1C90F690645F8A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000E54</idno>
<idno type="wicri:Area/Istex/Curation">000E54</idno>
<idno type="wicri:Area/Istex/Checkpoint">002717</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Stern M:double:blind:randomized</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients</title>
<author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pennsylvania, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marek, Kenneth L" sort="Marek, Kenneth L" uniqKey="Marek K" first="Kenneth L." last="Marek">Kenneth L. Marek</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Yale University School of Medicine, New Haven, Connecticut</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Friedman, Joseph" sort="Friedman, Joseph" uniqKey="Friedman J" first="Joseph" last="Friedman">Joseph Friedman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Brown University School of Medicine, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Neurology, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, Detroit, and Clinical Neuroscience Center, Southfield, Michigan</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Beth Israel Deaconess Medical Center, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mount Sinai School of Medicine, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2004-08">2004-08</date>
<biblScope unit="vol">19</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="916">916</biblScope>
<biblScope unit="page" to="923">923</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">06152E8AE57392DB334A8634EF1C90F690645F8A</idno>
<idno type="DOI">10.1002/mds.20145</idno>
<idno type="ArticleID">MDS20145</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term>
<term>monoamine oxidase inhibitors</term>
<term>monotherapy</term>
<term>rasagiline</term>
<term>safety</term>
<term>tolerability</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Rasagiline (N‐propargyl‐1(R)‐aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase‐B inhibitor. This study was designed to evaluate the safety, tolerability, and preliminary efficacy of rasagiline monotherapy in early Parkinson's disease (PD) patients not receiving levodopa. The study was performed as a multicenter, parallel‐group, double‐blind, randomized, placebo‐controlled, 10‐week study. Fifty‐six PD patients were randomly assigned to rasagiline mesylate 1, 2, or 4 mg once daily, or placebo. A 3‐week dose‐escalation period was followed by a 7‐week maintenance phase. At week 10, the mean (±SE) changes from baseline in total Unified Parkinson's Disease Rating Scale (UPDRS) score were −1.8 (±1.3), −3.6 (±1.7), −3.6 (±1.2), and −0.5 (±0.8) in the rasagiline 1, 2, and 4 mg/day and placebo groups, respectively. Analysis of responders showed that 28% of patients (12 of 43) receiving rasagiline had an improvement in total UPDRS score of greater than 30%, compared with none of the patients receiving placebo (P < 0.05, Fisher's exact test). The frequency and types of adverse events reported by rasagiline‐treated and placebo‐treated patients were similar. These results suggest that rasagiline monotherapy is well tolerated and efficacious in early PD. © 2004 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.</title>
<author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B" last="Stern">Matthew B. Stern</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Pennsylvania, Philadelphia, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pennsylvania, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marek, Kenneth L" sort="Marek, Kenneth L" uniqKey="Marek K" first="Kenneth L" last="Marek">Kenneth L. Marek</name>
</author>
<author><name sortKey="Friedman, Joseph" sort="Friedman, Joseph" uniqKey="Friedman J" first="Joseph" last="Friedman">Joseph Friedman</name>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A" last="Lewitt">Peter A. Lewitt</name>
</author>
<author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15300656</idno>
<idno type="pmid">15300656</idno>
<idno type="doi">10.1002/mds.20145</idno>
<idno type="wicri:Area/PubMed/Corpus">003388</idno>
<idno type="wicri:Area/PubMed/Curation">003388</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003482</idno>
<idno type="wicri:Area/Ncbi/Merge">000E96</idno>
<idno type="wicri:Area/Ncbi/Curation">000E96</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000E96</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Stern M:double:blind:randomized</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.</title>
<author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B" last="Stern">Matthew B. Stern</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Pennsylvania, Philadelphia, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pennsylvania, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marek, Kenneth L" sort="Marek, Kenneth L" uniqKey="Marek K" first="Kenneth L" last="Marek">Kenneth L. Marek</name>
</author>
<author><name sortKey="Friedman, Joseph" sort="Friedman, Joseph" uniqKey="Friedman J" first="Joseph" last="Friedman">Joseph Friedman</name>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A" last="Lewitt">Peter A. Lewitt</name>
</author>
<author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Incidence</term>
<term>Indans (pharmacokinetics)</term>
<term>Indans (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Monoamine Oxidase Inhibitors (pharmacokinetics)</term>
<term>Monoamine Oxidase Inhibitors (therapeutic use)</term>
<term>Multicenter Studies as Topic</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Indans</term>
<term>Monoamine Oxidase Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Indans</term>
<term>Monoamine Oxidase Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Multicenter Studies as Topic</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Rasagiline (N-propargyl-1(R)-aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase-B inhibitor. This study was designed to evaluate the safety, tolerability, and preliminary efficacy of rasagiline monotherapy in early Parkinson's disease (PD) patients not receiving levodopa. The study was performed as a multicenter, parallel-group, double-blind, randomized, placebo-controlled, 10-week study. Fifty-six PD patients were randomly assigned to rasagiline mesylate 1, 2, or 4 mg once daily, or placebo. A 3-week dose-escalation period was followed by a 7-week maintenance phase. At week 10, the mean (+/-SE) changes from baseline in total Unified Parkinson's Disease Rating Scale (UPDRS) score were -1.8 (+/-1.3), -3.6 (+/-1.7), -3.6 (+/-1.2), and -0.5 (+/-0.8) in the rasagiline 1, 2, and 4 mg/day and placebo groups, respectively. Analysis of responders showed that 28% of patients (12 of 43) receiving rasagiline had an improvement in total UPDRS score of greater than 30%, compared with none of the patients receiving placebo (P < 0.05, Fisher's exact test). The frequency and types of adverse events reported by rasagiline-treated and placebo-treated patients were similar. These results suggest that rasagiline monotherapy is well tolerated and efficacious in early PD.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005694 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005694 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:06152E8AE57392DB334A8634EF1C90F690645F8A |texte= Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |